Show simple item record

dc.contributor.authorYoung, R*
dc.contributor.authorPoyser, C*
dc.contributor.authorCrack, L*
dc.contributor.authorDockrell, D*
dc.contributor.authorBowman, C*
dc.contributor.authorBillingham, L*
dc.contributor.authorBower, M*
dc.contributor.authorWestwell, S*
dc.contributor.authorLeahy, Michael G*
dc.contributor.authorWoll, P*
dc.date.accessioned2016-01-06T10:08:21Zen
dc.date.available2016-01-06T10:08:21Zen
dc.date.issued2015en
dc.identifier.citationA UK national phase I/II clinical trial of a MEK1/2 inhibitor combined with highly active anti-retroviral therapy for HIV-associated Kaposi's sarcoma. 2015, 51 S699-S699 Eur J Canceren
dc.identifier.urihttp://hdl.handle.net/10541/592909en
dc.language.isoenen
dc.titleA UK national phase I/II clinical trial of a MEK1/2 inhibitor combined with highly active anti-retroviral therapy for HIV-associated Kaposi's sarcomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Sheffield, Academic Unit of Clinical Oncology, Sheffielden
dc.identifier.journalEuropean Journal of Canceren


This item appears in the following Collection(s)

Show simple item record